MAPT and Alzheimer disease: Every athlete participant was screened for the presence of AD pathology using either: (1) blood p-tau181; (2) CSF measures of Aβ42, p-tau, and t-tau; or (3) both blood p-tau181 and CSF markers of Aβ42, p-tau, and t-tau.